Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GEN1119 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation (Part 1): GEN1119 | EXPERIMENTAL | Participants will receive a number of dose levels (DLs) of GEN1119. |
| Dose Refinement (Part 2): GEN1119 | EXPERIMENTAL | Participants will be randomized to receive a number of DLs of GEN1119. |
| Expansion (Part 3): GEN1119 | EXPERIMENTAL | Participants with certain solid tumours will receive GEN1119 at the recommended expansion dose(s) as defined in Parts 1 and/or 2. |
| Name | Type | Description |
|---|---|---|
| GEN1119 | DRUG | Administered at certain DLs on specified days. |
Key Inclusion Criteria: * Have histologically or cytologically confirmed diagnosis of protocol-specified solid tumours. * Have progressed on standard of care (SoC) therapy applicable for the tumor type, or for whom there is no available SoC therapy likely to provide clinical benefit, and for whom e...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
GEN1119 is an investigational small molecule being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development, and no efficacy or safety data have been reported yet. The drug is not approved by regulatory authorities and remains under investigation.
GEN1119 is being developed by Genmab A/S, a biopharmaceutical company listed on the Nasdaq under the ticker GMAB. The company is conducting a Phase 1 clinical trial to evaluate the drug in participants with solid tumors.
GEN1119 is in Phase 1 clinical development. A Phase 1 trial is currently recruiting participants with solid tumors. The drug is investigational and has not been approved by regulatory authorities. Its safety and efficacy are still being evaluated in clinical studies.
GEN1119 is being studied in a Phase 1 clinical trial with the identifier NCT07695831, titled "A Phase 1 Trial of GEN1119 in Participants With Solid Tumors." The trial is actively recruiting and aims to enroll 112 participants in France and Japan.
Yes, the Phase 1 clinical trial of GEN1119 (NCT07695831) is randomized and controlled, but it is not double-blinded. The study is enrolling participants with solid tumors and is currently recruiting in France and Japan.